Templated high density lipoprotein nanoparticles as potential therapies and for molecular delivery

Advanced Drug Delivery Reviews

Volumn 65, Issue 5, 2013, Pages 649-662

  Damiano, Marina G ^a   Mutharasan, R Kannan ^b   Tripathy, Sushant ^a,b   McMahon, Kaylin M ^a,b   Thaxton, C Shad ^b,c,d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Institute for BioNanotechnology and Medicine (IBNAM)   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Atherosclerosis; Biomimetic; Bionanotechnology; Cancer; Spherical HDL; Targeted drug delivery; Therapy

Indexed keywords

ATHEROSCLEROSIS; BIONANOTECHNOLOGY; CANCER; SPHERICAL HDL; TARGETED DRUG DELIVERY; THERAPY;

BIOMIMETICS; CHOLESTEROL; DRUG DELIVERY; LIPOPROTEINS; NANOPARTICLES; SCAFFOLDS (BIOLOGY); SPHERES; SURFACE CHEMISTRY;

DISEASES;

CURCUMIN; DIAGNOSTIC AGENT; DRUG CARRIER; HIGH DENSITY LIPOPROTEIN; IMAGING AGENT; NANOPARTICLE; NANOSPHERE; NUCLEIC ACID; RECOMBINANT HIGH DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; DRUG DELIVERY SYSTEM; DRUG SYNTHESIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; STRUCTURE ACTIVITY RELATION; SURFACE PROPERTY;

ANIMALS; CARDIOVASCULAR DISEASES; DRUG DELIVERY SYSTEMS; HUMANS; LIPOPROTEINS, HDL; MOLECULAR TARGETED THERAPY; NANOPARTICLES;

EID: 84878344661     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.07.013     Document Type: Review

References (129)

1. Lloyd-Jones D., Adams R.J., Brown T.M., Carnethon M., Dai S., De Simone G., Ferguson T.B., Ford E., Furie K., Gillespie C., Go A., Greenlund K., Haase N., Hailpern S., Ho P.M., Howard V., Kissela B., Kittner S., Lackland D., Lisabeth L., Marelli A., McDermott M.M., Meigs J., Mozaffarian D., Mussolino M., Nichol G., Roger V.L., Rosamond W., Sacco R., Sorlie P., Thom T., Wasserthiel-Smoller S., Wong N.D., Wylie-Rosett J. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010, 121:e46-e215.
2. Genest J., Libby P. Braunwald's Heart Disease - A Textbook of Cardiovascular Medicine 2011, Elsevier Saunders. R.O. Bonow, D.L. Mann, D.P. Zipes, P. Libby (Eds.).
3. Lusis A.J. Atherosclerosis. Nature 2000, 407:233-241.
4. Falk E. Pathogenesis of atherosclerosis. J. Am. Coll. Cardiol. 2006, 47:C7-C12.
5. Khera A.V., Rader D.J. Future therapeutic directions in reverse cholesterol transport. Curr. Atheroscler. Rep. 2010, 12:73-81.
6. Jonas A., Phillips M.C. Lipoprotein structure. Biochemistry of Lipids, Lipoproteins and Membranes 2008, 485-506. Elsevier. D.E. Vance, J.E. Vance (Eds.).
7. Nofer J., Kehrel B., Fobker M., Levkau B., Assmann G., Eckardstein A.v. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 2002, 161:1-16.
8. Sikorski J.A. Atherosclerosis/lipoprotein/cholesterol metabolism. Comprehensive Medicinal Chemistry II 2007, 459-494. Elsevier Ltd. J.B. Taylor, D.J. Triggle (Eds.).
9. Segrest J.P., Jones M.K., Klon A.E., Sheldahl C.J., Hellinger M., Loof H.D., Harvey S.C. A detailed molecular belt model for apolipoprotein A-I in discoidal high density lipoprotein. J. Biol. Chem. 1999, 274:31755-31758.
10. Davidson W.S., Hillard G.M. The spatial organization of apolipoprotein A-I on the edge of discoidal high density lipoprotein particles. J. Biol. Chem. 2003, 278:27199-27207.
11. Glomset J.A. The plasma lecithin:cholesterol actyltransferase reaction. J. Lipid Res. 1968, 9:155-167.
12. Movva R., Rader D.J. Laboratory assessment of HDL heterogeneity and function. Clin. Chem. 2008, 54:788-800.
13. Cheung M.C., Albers J.J. Distribution of high density lipoprotein particles with different apoprotein composition: particles with A-I and A-II and particles with A-I but no A-II. J. Lipid Res. 1982, 23:747-753.
14. Vaisar T., Pennathur S., Green P.S., Gharib S.A., Hoofnagle A.N., Cheung M.C., Byun J., Vuletic S., Kassim S., Singh P., Chea H., Knopp R.H., Brunzell J., Geary R., Chait A., Zhao X., Elkon K., Marcovina S., Ridker P., Oram J.F., Heinecke J.W. Shotgun proteomics implicates protease inhibition and complement activation in antiinflammatory properties of HDL. J. Clin. Invest. 2007, 117:746-756.
15. Vickers K.C., Palmisano B.T., Shoucri B.M., Shamburek R.D., Remaley A.T. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell Biol. 2011, 13:423-433.
16. Rye K., Barter P.J. The influence of apolipoproteins on the structure and function of spheroidal, reconstituted high density lipoproteins. J. Biol. Chem. 1994, 269:10298-10303.
17. Wilson P.W., Abbott R.D., Castelli W.P. High density lipoprotein cholesterol and mortality. The Framingham Heart study. Arterioscler. Thromb. Vasc. Biol. 1988, 8:737-741.
18. Maxfield F.R., Tabas I. Role of cholesterol and lipid organization in disease. Nature 2005, 438:612-621.
19. Chamberlain A.M., Folsom A.R., Heckbert S.R., Rosamond W.D., Cushman M. High-density lipoprotein cholesterol and venous thromboembolism in the Longitudinal Investigation of Thromboembolism Etiology (LITE). Blood 2008, 112:2675-2680.
20. Rader D.J., Alexander E.T., Weibel G.L., Billheimer J., Rothblat G.H. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J. Lipid Res. 2009, 50:S189-S194.
21. Fielding C.J., Fielding P.E. Molecular physiology of reverse cholesterol transport. J. Lipid Res. 1995, 36:211-228.
22. Wang M., Briggs M.R. HDL: the metabolism, function, and therapeutic importance. Chem. Rev. 2004, 104:119-137.
23. Wang N., Silver D.L., Costet P., Tall A.R. Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1. J. Biol. Chem. 2000, 275:33053-33058.
24. Gelissen I.C., Harris M., Rye K., Quinn C., Brown A.J., Kockx M., Cartland S., Packianathan M., Kritharides L., Jessup W. ABCA1 and ABCG1 synergize to mediate cholesterol export to ApoA-I. Arterioscler. Thromb. Vasc. Biol. 2006, 26:534-540.
25. Wang N., Lan D., Chen W., Matsuura F., Tall A.R. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc. Natl. Acad. Sci. 2004, 101:9774-9779.
26. Rader D.J. Molecular regulation of HDL metabolism and function: implications for novel therapies. J. Clin. Invest. 2006, 116:3090-3100.
27. Silver D.L., Wang N., Xiao X., Tall A.R. High density lipoprotein (HDL) particle uptake mediated by scavenger receptor class B type 1 results in selective sorting of HDL cholesterol from protein and polarized cholesterol secretion. J. Biol. Chem. 2001, 276:25287-25293.
28. Trigatti B.L., Rigotti A., Braun A. Cellular and physiological roles of SR-BI, a lipoprotein receptor which mediates selective lipid uptake. Biochim. Biophys. Acta 2000, 1529:276-286.
29. Seetharam D., Mineo C., Gormley A.K., Gibson L.L., Vongpatanasin W., Chambliss K.L., Hahner L.D., Cummings M.L., Kitchens R.L., Marcel Y.L., Rader D.J., Shaul P.W. High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I. Circ. Res. 2006, 98:63-72.
30. 3. J. Clin. Invest. 2004, 113:569-581.
31. Yuhanna I.S., Zhu Y., Cox B.E., Hahner L.D., Osborne-Lawrence S., Lu P., Marcel Y.L., Anderson R.G.W., Mendelsohn M.E., Hobbs H.H., Shaul P.W. High-density lipoprotein binding to scavenger receptor-B1 activates endothelial nitric oxide synthase. Nat. Med. 2001, 7:853-857.
32. Suc I., Escargueil-Blanc I., Troly M., Salvayre R., Negre-Salvayre A. HDL and ApoA prevent cell death of endothelial cells induced by cxidized LDL. Arterioscler. Thromb. Vasc. Biol. 1997, 17:2158-2166.
33. Sugano M., Tsuchida K., Makino N. High-density lipoproteins protect endothelial cells from tumor necrosis factor-a-induced apoptosis. Biochem. Biophys. Res. Commun. 2000, 272:872-876.
34. Kontush A., Chapman M.J. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr. Opin. Lipidol. 2010, 21:312-318.
35. Kontush A., Chapman M.J. Antiatherogenic small, dense HDL - guardian angel of the arterial wall?. Nat. Clin. Pract. Cardiovasc. Med. 2006, 3:144-153.
36. Nobecourt E., Jacqueminet S., Hansel B., Chantepie S., Grimaldi A., Chapman M.J., Kontush A. Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia. Diabetologica 2005, 48:529-538.
37. Hansel B., Giral P., Nobecourt E., Chantepie S., Bruckert E., Chapman M.J., Kontush A. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J. Clin. Endocrinol. Metab. 2004, 89:4963-4971.
38. Cockerill G.W., Rye K., Gamble J.R., Vadas M.A., Barter P.J. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler. Thromb. Vasc. Biol. 1995, 15:1987-1994.
39. Boden W.E., Probstfield J.L., Anderson T., Chaitman B.R., Desvignes-Nickens P., Koprowicz K., McBride R., Teo K., Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 2011, 365:2255-2267.
40. Barter P.J., Caulfield M., Eriksson M., Grundy S.M., Kastelein J.J., Komajda M., Lopez-Sendon J., Mosca L., Tardif J.C., Waters D.D., Shear C.L., Revkin J.H., Buhr K.A., Fisher M.R., Tall A.R., Brewer B. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 2007, 357:2109-2122.
41. Siperstein M.D. Role of cholesterolgenesis and isoprenoid synthesis in DNA replication and cell growth. J. Lipid Res. 1984, 25:1462-1468.
42. Leon C.G., Locke J.A., Adomat H.H., Etinger S.L., Twiddy A.L., Neumann R.D., Nelson C.C., Guns E.S., Wasan K.M. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. Prostate 2010, 70:390-400.
43. Hofland J., van Weerden W.M., Dits N.F.J., Steenbergen J., van Leenders G.J.L.H., Jenster G., Schroeder F.H., de Jong F.H. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res. 2010, 70:1256-1264.
44. Hynds S.A., Welsh J., Stewart J.M., Jack A., Soukop M., McArdle C.S., Calman K.C., Packard C.J., Shepherd J. Low-density lipoprotein metabolism in mice with soft tissue tumours. Biochim. Biophys. Acta 1984, 795:589-595.
45. Vitols S., Norgren S., Juliusson G., Tatidis L., Luthman H. Multilevel regulation of low-density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in normal and leukemic cells. Blood 1994, 84:2689-2698.
46. Ho Y.K., Smith R.G., Brown M.S., Goldstein J.L. Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells. Blood 1978, 52:1099-1114.
47. Tosi M.R., Tugnoli V. Cholesteryl esters in malignancy. Clin. Chim. Acta 2005, 359:27-45.
48. Pussinen P.J., Karten B., Wintersperger A., Reicher H., McLean M., Malle E., Sattler W. The human breast carcinoma cell lines HBL-100 acquires exogenous cholesterol from high-density lipoprotein via CLA-1 (CD-36 and LIMPII analogous 1) - mediated selective cholesteryl ester uptake. Biochem. J. 2000, 349:559-566.
49. Shahzad M.M.K., Mangala L.S., Han H.D., Lu C., Bottsford-Miller J., Nishimura M., Mora E.M., Lee J., Stone R.L., Pecot C.V., Thanapprapasr D., Roh J., Gaur P., Nair M.P., Park Y., Sabnis N., Deavers M.T., Lee J., Ellis L.M., Lopez-Berestein G., McConathy W.J., Prokaj L., Lacko A.G., Sood A.K. Targeted delivery of small interefering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia 2011, 13:309-319.
50. Imachi H., Murao K., Sayo Y., Hosokawa H., Sato M., Niimi M., Kobayashi S., Miyauchi A., Ishida T., Takahara J. Evidence for a potential role for HDL as an important source of cholesterol in human adrenocortical tumors via the CLA-1 pathway. Endocr. J. 1999, 46:27-34.
51. Rao R.M., Jo Y., Leers-Sucheta S., Bose H.S., Miller W.L., Azhar S., Stocco D.M. Differential regulation of steroid hormone biosynthesis in R2C and MA-10 Leydig tumor cells: role of SR-B1-mediated selective cholesteryl ester transport. Biol. Reprod. 2003, 68:114-121.
52. Mooberry L.K., Nair M., Paranjape S., McConathy W.J., Lacko A.G. Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier. J. Drug Target. 2010, 18:53-58.
53. McGrowder D., Riley C., Morrison E.Y.S.A., Gordon L. The role of high-density lipoproteins in reducing the risk of vascular diseases, neurogenerative disorders, and cancer. Cholesterol 2011, 2011.
54. Joy T., Hegele R.A. Is raising HDL a futile strategy for atheroprotection?. Nat. Rev. Drug Discov. 2008, 7:143-155.
55. Luthi A.J., Patel P.C., Ko C.H., Mutharasan R.K., Mirkin C.A., Thaxton C.S. Nanotechnology for synthetic high-density lipoproteins. Trends Mol. Med. 2010, 16:553-560.
56. Plump A.S., Scott C.J., Breslow J.L. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc. Natl. Acad. Sci. 1994, 91:9607-9611.
57. Nanjee M.N., Crouse J.R., King J.M., Hovorka R., Rees S.E., Carson E.R., Morgenthaler J.J., Lerch P., Miller N.E. Effects of intravenous infusion of lipid-free Apo A-I in humans. Arterioscler. Thromb. Vasc. Biol. 1996, 16:1203-1214.
58. Tardif J., Gregoire J., L'Allier P.L., Ibrahim R., Lesperance J., Heinonen T.M., Kouz S., Berry C., Basser R., Lavoie M., Guertin M., Rodes-Cabau J. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis. JAMA 2007, 297:1675-1682.
59. Franceschini G., Sirtori C.R., Capurso A.n., Weisgraber K.H., Mahley R.W. A-I Milano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J. Clin. Invest. 1980, 66:892-900.
60. Nissen S.E., Tsunoda T., Tuzcu E.M., Schoenhagen P., Cooper C.J., Yasin M., Eaton G.M., Lauer M.A., Sheldon W.S., Grines C.L., Halpern S., Crowe T., Blankenship J.C., Kerensky R. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes. JAMA 2003, 290:2292-2300.
61. Anantharamaiah G.M., Jones J.L., Brouillette C.G., Schmidt C.F., Chung B.H., Hughes T.A., Bhown A.S., Segrest J.P. Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine. J. Biol. Chem. 1985, 260:10248-10255.
62. Navab M., Schechter I., Anantharamaiah G.M., Reddy S.T., Van Lenten B.J., Fogelman A.M. Structure and function of HDL mimetics. Arterioscler. Thromb. Vasc. Biol. 2010, 30:164-168.
63. Navab M., Anantharamaiah G.M., Hama S., Garber D.W., Chaddha M., Hough G., Lallone R., Fogelman A.M. Oral administration of an apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 2002, 105:290-292.
64. Nandedkar S.D., Weihrauch D., Xu H., Shi Y., Feroah T., Hutchins W., Rickaby D.A., Duzgunes N., Hillery C.A., Konduri K.S., Pritchard K.A.J. D-4F, an ApoA-1 mimetic, decreases airway hyperresponsiveness, inflammation, and oxidative stress in a murine model of asthma. J. Lipid Res. 2010, 52:499-508.
65. Jonas A. Reconsitution of high-density lipoproteins. Methods Enzymol. 1986, 128:553-582.
66. Sparks D.L., Pritchard P.H. The neutral lipid composition and size of recombinant high density lipoproteins regulates lecithin:cholesterol acyltransferase activity. Biochem. Cell Biol. 1988, 67:358-363.
67. Ritter M.C., Scanu A.M. Role of apolipoprotein A-I in the structure of human serum high density lipoproteins. J. Biol. Chem. 1977, 252:1208-1216.
68. Cho K., Kim J. A reconstituted HDL containing V156K or R173C apoA-I exhibited anti-inflammatory activity in apo-E deficient mice and showed resistance to myeloperozidase-mediated oxidation. Exp. Mol. Med. 2009, 41:417-428.
69. Shah P.K., Yano J., Reyes O., Chyu K., Kaul S., Isgaier C.L., Drake S., Cercek B. Circulation 2001, 103:3047-3050.
70. Murphy A.J., Chin-Dusting J., Sviridov D. Reconstituted HDL: a therapy for atherosclerosis and beyond. Clin. Lipidol. 2009, 4:731-739.
71. Shaw J.A., Bobik A., Murphy A., Kanellakis P., Blombery P., Mukhamedova N., Wollard K., Lyon S., Sviridov D., Dart A.M. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ. Res. 2008, 103:1084-1091.
72. Patel S., Drew B.G., Nakhla S., Duffy S.J., Murphy A.J., Barter P.J., Rye K., Chin-Dusting J., Hoang A., Sviridov D., Celermajer D.S., Kingwell B.A. Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. J. Am. Coll. Cardiol. 2009, 53:962-971.
73. Redgrave T.G., Roberts D.C.K., West C.E. Separation of plasma lipoproteins by density-gradient ultracentrifugation. Anal. Biochem. 1975, 65:42-49.
74. Sherman C.B., Peterson S.J., Frishman W.H. Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis. Cardiol. Rev. 2010, 18:141-147.
75. Cormode D.P., Briley-Saebo K.C., Mulder W.J.M., Aguinaldo J.G.S., Barazza A., Ma Y., Fisher E.A., Fayad Z.A. An ApoA-I mimetic peptide high-density-lipoprotein-based MRI contrast agent for atherosclerotic plaque composition detection. Small 2008, 4:1437-1444.
76. Cormode D.P., Chandrasekar R., Delshad A., Briley-Saebo K.C., Calcagno C., Barazza A., Mulder W.J.M., Fisher E.A., Fayad Z.A. Comparison of synthetic high density lipoprotein (HDL) contrast agents for MR imaging of atherosclerosis. Bioconjug. Chem. 2009, 20:937-943.
77. Zhang Z., Cao W., Jin H., Lovell J.F., Yang M., Ding L., Chen J., Corbin I., Luo Q., Zheng G. Biomimetic nanocarrier for direct cytosolic drug delivery. Angew. Chem. Int. Ed. 2009, 48:9171-9175.
78. Ryan R.O. Nanodisks: hydrophobic drug delivery vehicles. Expert Opin. Drug Deliv. 2008, 5:343-351.
79. Redmond K.A., Nguyen T., Ryan R.O. All-trans-retinoic acid nanodisks. Int. J. Pharm. 2007, 339:246-250.
80. Kuyucu N. Amphotericin B use in children: conventional and lipid-based formulations. Expert Rev. Anti Infect. Ther. 2011, 9:357-367.
81. Oda M.N., Hargreaves P.L., Beckstead J.A., Redmond K.A., Antwerpen R.v., Ryan R.O. Reconstituted high density lipoprotein enriched with the polyene antibiotic amphotericin B. J. Lipid Res. 2006, 47:260-267.
82. Park J.H., Tallman M.S. Treatment of acute promyelocytic leukemia without cytotoxic chemotherapy. Oncology 2011, 25:733.
83. Singh A.T.K., Evens A.M., Anderson R.J., Beckstead J.A., Sankar N., Sassano A., Bhalla S., Yang S., Platanias L.C., Forte T.M., Ryan R.O., Gordon L.I. All trans retinoic acid nanodisks enhance retinoic acid receptor mediated apoptosis and cell cycle arrest in mantle cell lymphoma. Br. J. Haematol. 2010, 150:158-169.
84. Ghosh M., Singh A.T.K., Xu W., Sulchek T., Gordon L.I., Ryan R.O. Curcumin nanodisks: formulation and characterization, Nanomed. Nanotechnol. Biol. Med. 2011, 7:162-167.
85. Singh A.T.K., Ghosh M., Forte T.M., Ryan R.O., Gordon L.I. Curcumin nanodisk-induced apoptosis in mantle cell lymphoma. Leuk. Lymphoma 2011, 52:1537-1543.
86. Frias J.C., Williams K.J., Fisher E.A., Fayad Z.A. Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J. Am. Chem. Soc. 2004, 125:16316-16317.
87. Frias J.C., Ma Y., Williams K.J., Fayad Z.A., Fisher E.A. Properties of a versatile nanoparticle platform contrast agent to image and characterize atherosclerotic plaques by magnetic resonance imaging. Nano Lett. 2006, 6:2220-2224.
88. Jonas A., Kezdy K.E., Williams M.I., Rye K. Lipid transfers between reconstituted high density lipoprotein complexes and low density lipoproteins: effects of plasma protein factors. J. Lipid Res. 1998, 29:1349-1357.
89. Silva R.A.G.D., Huang R., Morris J., Feng J., Gracheva E.O., Ren G., Kontush A., Jerome W.G., Rye K., Davidson W.S. Structure of apolipoprotein A-I in spherical high density lipoproteins of different sizes. Proc. Natl. Acad. Sci. 2008, 105:12176-12181.
90. Rye K., Hime N.J., Barter P.J. The influence of cholesteryl ester transfer protein on the composition, size, and structure of spherical, reconstituted high density lipoproteins. J. Biol. Chem. 1995, 270:189-196.
91. Huang R., Silva R.A.G.D., Jerome W.G., Kontush A., Chapman M.J., Curtiss L.K., Hodges T.J., Davidson W.S. Apolipoprotein A-I structural organization in high-density lipoproteins isolated from human plasma. Nat. Struct. Mol. Biol. 2011, 18:416-423.
92. Asztalos B.F., Tani M., Schaefer E.J. Metabolic and functional relevance of HDL subspecies. Curr. Opin. Lipidol. 2011, 22:176-185.
93. Asztalos B.F., Collins D., Cupples L.A., Demissie S., Horvath K.V., Bloomfield H.E., Robins S.J., Schaefer E.J. Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL intervention trial. Arterioscler. Thromb. Vasc. Biol. 2005, 25:2185-2191.
94. Asztalos B.F., Cupples L.A., Demissie S., Horvath K.V., Cox C.E., Batista M.C., Schaefer E.J. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring study. Arterioscler. Thromb. Vasc. Biol. 2004, 24:2181-2187.
95. Bergmeier C., Siekmeier R., Gross W. Distribution spectrum of paraoxonase activity in HDL fractions. Clin. Chem. 2004, 50:2309-2315.
96. Zhang Z., Chen J., Ding L., Jin H., Lovell J.F., Corbin I.R., Cao W., Lo P., Yang M., Tsao M., Luo Q., Zheng G. HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting. Small 2010, 6:430-437.
97. Thaxton C.S., Daniel W.L., Giljohann D.A., Thomas A.D., Mirkin C.A. Templated spherical high density lipoprotein nanoparticles. J. Am. Chem. Soc. 2009, 131:1384-1385.
98. Cormode D.P., Skajaa T., Schooneveld M.M.v., Koole R., Jarzyna P., Lobatto M.E., Calcagno C., Barazza A., Gordon R.E., Zanzonico P., Fisher E.A., Fayad Z.A., Mulder W.J.M. Nanocrystal core high-density lipoproteins: a multimodality contrast agent platform. Nano Lett. 2008, 8:3715-3723.
99. Luthi A.J., Zhang H., Kim D., Giljohann D.A., Mirkin C.A., Thaxton C.S. Tailoring of biomimetic high-density lipoprotein nanostructures changes cholesterol binding and efflux. ACS Nano 2012, 6:276-285.
100. McMahon K.M., Mutharasan R.K., Tripathy S., Veliceasa D., Bobeica M., Shumaker D.K., Luthi A.J., Helfand B.T., Ardehali H., Mirkin C.A., Volpert O., Thaxton C.S. Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery. Nano Lett. 2011, 11:1208-1214.
101. Skajaa T., Cormode D.P., Jarzyna P.A., Delshad A., Blachford C., Barazza A., Fisher E.A., Gordon R.E., Fayad Z.A., Mulder W.J.M. The biological properties of iron oxide core high-density lipoprotein in experimental atherosclerosis. Biomaterials 2011, 32:206-213.
102. Patel P.C., Giljohann D.A., Daniel W.L., Zheng D., Prigodich A.E., Mirkin C.A. Scavenger receptors mediate cellular uptake of polyvalent oligonucleotide-functionalized gold nanoparticles. Bioconjug. Chem. 2010, 21:2250-2256.
103. Rink J.S., McMahon K.M., Chen X., Mirkin C.A., Thaxton C.S., Kaufman D.B. Transfection of pancreatic islets using polyvalent DNA-funtionalized gold nanoparticles. Surgery 2010, 148:335-345.
104. Davis M.E., Chen Z., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 2008, 7:771-782.
105. McConathy W.J., Nair M.P., Paranjape S., Mooberry L., Lacko A.G. Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel. Anticancer Drugs 2008, 19:183-188.
106. Matz C., Jonas A. Micellar complexes of human apolipoprotein A-I with phosphatidylcholines and cholesterol prepared from cholate-lipid dispersion. J. Biol. Chem. 1982, 257:4535-4540.
107. Acton S., Rigotti A., Landschulz K.T., Xu S., Hobbs H.H., Krieger M. Identification of scavenger receptor SR-B1 as a high density lipoprotein receptor. Science 1996, 271:518-520.
108. Whitehead K.A., Langer R., Anderson D.G. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 2009, 8:129-138.
109. Soutschek J., Akinc A., Bramlage B., Charisse K., Constien R., Donoghue M., Elbashir S., Geick A., Hadwiger P., Harborth J., John M., Kesavan V., Lavine G., Pandey R.K., Racie T., Rajeev K.G., Roehl I., Toudjarska I., Wang G., Wuschko S., Bumcrot D., Koteliansky V., Limmer S., Manoharan M., Vornlocher H. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004, 432:173-178.
110. Lorenz C., Hadwiger P., John M., Vornlocher H., Unverzagt C. Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg. Med. Chem. Lett. 2004, 14:4975-4977.
111. Jackson A.L., Burchard J., Leake D., Reynolds A., Schelter J., Guo J., Johnson J.M., Lim L., Karpilow J., Nichols K., Marshall W., Khvorova A., Linsley P.S. Position-specific chemical modification of siRNAs reduced "off-target" transcript silencing. RNA 2006, 12:1197-1205.
112. Allerson C.R., Sioufi N., Jarres R., Prakash T.P., Naik N., Berdeja A., Wanders L., Griffey R.H., Swayze E.E., Bhat B. Fully 2'-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfereing RNA. J. Med. Chem. 2005, 48:901-904.
113. Akinc A., Goldberg M., Qin J., Dorkin J.R., Gamba-Vitalo C., Maier M., Jayaprakash K.N., Jayaraman M., Rajeev K.G., Manoharan M., Koteliansky V., Roehl I., Leshchiner E.S., Langer R., Anderson D.G. Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol. Ther. 2009, 17:872-879.
114. Sutton D., Kim S., Shuai X., Leskov K., Marques J.T., Williams B.R.G., Boothman D.A., Gao J. Efficient suppression of secretory clusterin levels by polymer-siRNA nanocomplexes enhances ionizing radiation lethality in human MCF-7 breast cancer cells in vitro. Int. J. Nanomedicine 2006, 1:155-162.
115. Giljohann D.A., Seferos D.S., Prigodich A.E., Patel P.C., Mirkin C.A. Gene regulation with polyvalent siRNA-nanoparticle conjugates. J. Am. Chem. Soc. 2009, 131:2072-2073.
116. Alexis F., Pridgen E., Molnar L.K., Farokhzad O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 2008, 5:505-515.
117. Paillard A., Hindre F., Vignes-Colombeix C., Benoit J., Garcion E. The importance of endo-lysosomal escape with lipid nanocapsules for drug subcellular bioavailability. Biomaterials 2010, 31:7542-7554.
118. Panyam J., Zhou W., Prabha S., Sahoo S.K., Labhasetwar V. Rapid endo-lysosomal escape of poly (DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J. 2002, 16:1217-1226.
119. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46:6387-6392.
120. Greish K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J. Drug Target. 2007, 2007:457-464.
121. Nel A., Xia T., Maedler L., Li N. Toxic potential of materials at the nanolevel. Science 2006, 311:622-627.
122. Mishra S., Webster P., Davis M.E. PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. Eur. J. Cell Biol. 2004, 83:97-111.
123. Ichihara M., Shimizu T., Imoto A., Hashiguchi Y., Uehara Y., Ishida T., Kiwada H. Anti-PEG IgM response against PEGylated liposomes in mice and rats. Pharmaceutics 2011, 3:1-11.
124. Tagami T., Uehara Y., Moriyoshi N., Ishida T., Kiwada H. Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of the siRNA. J. Control. Release 2011, 151:149-154.
125. Davis M.E. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol. Pharm. 2009, 6:659-668.
126. Bijsterbosch M.K., Rump E.T., De Vrueh R.L.A., Dorland R., van Veghel R., Tivel K.L., Biessen E.A.L., van Berkel T.J.C., Manoharan M. Modulation of plasma protein binding and in vivo liver cell uptake of phosphorothioate oligodeoxynucleotides by cholesterol conjugation. Nucleic Acids Res. 2000, 28:2717-2725.
127. Wolfrum C., Shi S., Jayaprakash K.N., Jayaraman M., Wang G., Pandey R.K., Rajeev K.G., Nakayama T., Charrise K., Ndungo E.M., Zimmermann T., Koteliansky V., Manoharan M., Stoffel M. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat. Biotechnol. 2007, 25:1149-1157.
128. Kirschner M.B., Kao S.C., Edelman J.J., Armstrong N.J., Vallely M.P., van Zandwijk N., Reid G. Haemolysis during sample preparation alters microRNA content of plasma. PLoS One 2011, 6:e24145.
129. Yang M., Jin H., Chen J., Ding L., Ng K.K., Lin Q., Lovell J.F., Zhang Z., Zheng G. Efficient cytosolic delivery of siRNA using HDL-mimicking nanoparticles. Small 2011, 7:568-573.